Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators will detect the expression of HBV-related HCC biomarker lncRNA SNHG15 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Detailed Description
-----------------
Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and lncRNA SNHG15 was detected by RT-PCR. At the same time, healthy subjects were selected as the control group, and lncRNA SNHG15 in blood was detected by RT-PCR. At the same time, the correlation between lncRNA SNHG15 and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed.

Official Title
-----------------
The First Affliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Conditions
-----------------
HCC

Intervention / Treatment
-----------------
* Diagnostic Test: No intervention was required for patients or control group in this study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The age and sex of the healthy control group were matched with that of HBV-associated patient group. There was no tumor in the other parts of the body, and no tumor in the blood system. The healthy control group did not have any liver benign diseases. There are no inflammatory diseases in other parts of the body; the functions of the liver, kidney, and heart were normal. Exclusion Criteria: The volunteer has tumors in the liver or other parts of the body, or blood system tumors; The volunteer has benign liver diseases; The patient has inflammatory disease elsewhere. If the volunteer has any one of the above diseases, it shall be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HBV-associated HCC group<br>The age and gender of patients are not limited. The patient was finally diagnosed as HBV-associated HCC by imaging examination and pathology. | Diagnostic Test: No intervention was required for patients or control group in this study<br>* The patient was treated normally and no intervention was required in this study<br>|
| negative control group<br>The age and sex of this group were matched with that of HBV-associated HCC patient group. The patient did not have any tumor but had HBV infection. The functions of the renal and heart were normal. | Diagnostic Test: No intervention was required for patients or control group in this study<br>* The patient was treated normally and no intervention was required in this study<br>|
| Healthy control group<br>The age and sex of the healthy control group were matched with that of HBV-associated HCC patient group. There was no tumor in the liver or other parts of the body, and no tumor in the blood system. The healthy control group did not have any liver benign diseases. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal. | Diagnostic Test: No intervention was required for patients or control group in this study<br>* The patient was treated normally and no intervention was required in this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of lncRNA SNHG15 in HBV-associated HCC patients before surgery | The expression of lncRNA SNHG15 in blood samples: The expressions of lncRNA SNHG15 in blood samples were detected by real-time fluorescence quantitative PCR method. | 1 to 3 days before surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of lncRNA SNHG15 in HBV-associated HCC patients 1 week after surgery | The expressions of lncRNA SNHG15 in tissues: In the tumor and adjacent tissues from HBV-associated HCC patients, the expressions of lncRNA SNHG15were measured by real-time fluorescence quantitative PCR method. The expression of lncRNA SNHG15 in blood samples: The expressions of lncRNA SNHG15 in blood samples were detected by real-time fluorescence quantitative PCR method. | one week after surgery | 
| Detection of lncRNA SNHG15 in HBV-associated HCC patients at 6 months after surgery | The expression of lncRNA SNHG15 in blood samples: The expressions of lncRNA SNHG15 in blood samples were detected by real-time fluorescence quantitative PCR method. | 6 months postoperatively | 
| Detection of lncRNA SNHG15 in the control groups as baseline | The expression of lncRNA SNHG15 in blood samples: The expressions of lncRNA SNHG15 in blood samples were detected by real-time fluorescence quantitative PCR method. | the level of lncRNA SNHG15 were detected as baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HBV related HCC